NVST - Envista Holdings announces FDA clearance for Nobel Biocare N1 implant system

Envista Holdings (NYSE:NVST) said that the FDA has granted its 510(k) clearance for the Nobel Biocare N1 implant system. A collection of instruments, prosthetic components, and surgical protocols, the N1 implant system is “a significant step forward in patient-centric implant solutions,” Envista (NVST) said. “Nobel Biocare N1™ system enables clinicians to set a new standard in personalizing, digitizing, and democratizing the implant treatment experience they can offer patients," CEO Amir Aghdaei remarked. Brea, California -based company exceeded the analyst expectations with its earnings release for Q3 2021 in November. Before that, BofA Securities upgraded the stock to Buy from Hold on recent weakness. The portfolio optimization and margin improvement "should set NVST up for potential accretive M&A. This would complement an improving core growth portfolio," the analyst Michael Cherny argued.

For further details see:

Envista Holdings announces FDA clearance for Nobel Biocare N1 implant system